

Application Number 10/017755

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (Currently Amended) An orally disintegrable tablet which comprises
    - (i) fine granules having an average particle diameter of 300 to 400  $\mu\text{m}$ , which fine granules comprise: (a) a core composition comprising excipient and 10 weight % or more of an acid-labile physiologically active substance, (b) an enteric coating layer for the core composition comprising a first component that is an enteric coating agent and a second component that is a sustained released sustained-release agent, and (c) a coating layer comprising mannitol outside the enteric coating layer; and
    - (ii) a water-soluble sugar alcohol, wherein said water-soluble sugar alcohol is comprised in the tablet separately from said fine granules (i) in said tablet and wherein the water-soluble sugar alcohol separate from said fine granules is in an amount of 5 to 97 weight % relative to 100 weight % of the orally disintegrable tablet apart from the fine granules;
- wherein said tablet having a hardness strength of about 1 to about 20 kg is orally disintegrable;
- and wherein the oral disintegration time for complete disintegration of said

Application Number 10/017755

tablet is one minute or less.

2. (Canceled)

3. (Original) An orally disintegrable tablet of claim 1, wherein the fine granules further comprise a basic inorganic salt.

4-6. (Canceled)

7. (Previously Presented) An orally disintegrable tablet of claim 1, wherein the particle diameter of the fine granules is practically 300 to 425  $\mu\text{m}$ .

8. (Canceled)

9. (Original) An orally disintegrable tablet of claim 1, wherein the acid-labile physiologically active substance is a benzimidazole compound or a salt thereof.

10. (Canceled)

11. (Original) An orally disintegrable tablet of claim 3, wherein the basic inorganic salt is a salt of magnesium and/or a salt of calcium.

12. (Previously Presented) An orally disintegrable tablet of claim 1, wherein

Application Number 10/017755

the core composition comprises a core being coated by a benzimidazole compound and a basic inorganic salt, said core comprising crystalline cellulose and lactose.

13. (Original) An orally disintegrable tablet of claim 12, wherein the core comprises 50 weight % or more of lactose.

14. (Original) An orally disintegrable tablet of claim 12, wherein the core comprises 40 to 50 weight % of crystalline cellulose and 50 to 60 weight % of lactose.

15. (Previously Presented) An orally disintegrable tablet of claim 1, wherein the core composition comprises 20 weight % or more of an acid-labile physiologically active substance.

16. (Previously-Presented) An orally disintegrable tablet of claim 1, wherein the core composition comprises 20 to 50 weight % of an acid-labile physiologically active substance.

17. (Original) An orally disintegrable tablet of claim 1, wherein the fine granules are produced by fluidized-bed granulation method.

18. (Original) An orally disintegrable tablet of claim 1, wherein the enteric coating layer comprises an aqueous enteric polymer agent.

Application Number 10/017755

19. (Original) An orally disintegrable tablet of claim 18, wherein the aqueous enteric polymer agent is a methacrylate copolymer.
20. (Canceled)
21. (Previously Presented) An orally disintegrable tablet of claim 1, wherein the sustained-release agent is a methacrylate copolymer.
22. (Previously Presented) An orally disintegrable tablet of claim 18, wherein the sustained-release agent is in an amount of 5 to 15 weight % relative to 100 weight % of the aqueous enteric polymer agent.
23. (Previously Presented) An orally disintegrable tablet of claim 1, wherein the water-soluble sugar alcohol in (ii) is erythritol.
24. (Previously Presented) An orally disintegrable tablet of claim 1, wherein the water-soluble sugar alcohol in (ii) is mannitol.
- 25-28. (Canceled)
29. (Original) An orally disintegrable tablet of claim 1, which further comprises crospovidone.

Application Number 10/017755

30. (Canceled)

31. (Original) An orally disintegrable tablet of claim 1, which comprises no lubricant inside the tablet.

32-49. (Canceled)

50. (Previously Presented) An orally disintegrable tablet of claim 1, wherein an additive selected from crystalline cellulose, low substituted hydroxypropyl cellulose or a combination thereof is further comprised in combination with said water-soluble sugar alcohol in (ii).

51. (Previously Presented) An orally disintegrable tablet of claim 50, wherein the crystalline cellulose is in an amount of 3 to 50 weight % relative to 100 weight % of the tablet apart from the fine granule.

52-53. (Canceled)

54. (Previously Presented) An orally disintegrable tablet of claim 9, wherein the benzimidazole compound is lansoprazole.